ALBO News and Press, Albireo Pharma Inc. From 01/22/21

BOSTON, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today joins the Alagille community in commemorating the second annual International Alagille Syndrome Awareness Day on Janua...

Albireo Pharma (ALBO) grants stock options to purchase up to 18.5K shares at an exercise price of $37.22/share (the Nasdaq closing price when granted, on January 11).The options have a 10-year term and vesting period of 4 years. For further details see: Albireo Pharma gra...

BOSTON, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced that it will host a virtual Commercial Day for investors on February 11 from 11:30-1:00pm EST. Presentation...

BOSTON, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will participate in the H.C. Wainwright Virtual BioConnec...

Heading into 2021, Baird keeps a neutral view on Biotechnology despite higher expectations after the sector with a 26% gain in the iShares Nasdaq Biotechnology ETF (IBB) outperformed in 2020 compared to the 16% in the SPDR S&P 500 Trust ETF (SPY). The outlook is underpinned by uncertainty...

Albireo Pharma (ALBO) initiates global Phase 3 trial, ASSERT, to evaluate odevixibat in patients with Alagille syndrome, a rare inherited disorder affecting the liver and other organs caused by bile duct abnormalities.Odevixibat is a non-systemic ileal bile acid transport inhibitor (IBAT...

- Study represents Albireo’s third global, Phase 3 trial in rare cholestatic liver diseases - - ASSERT gold standard study design in Alagille syndrome - - Product submission of once-daily odevixibat for patients with PFIC under review by FDA and EMA - ...

Albireo Pharma (ALBO) has submitted a New Drug Application ((NDA)) to the FDA and a Marketing Authorization Application ((MAA)) to the EMA seeking approval of odevixibat for the treatment of patients with progressive familial intrahepatic cholestasis ((PFIC)), a rare disorder that causes prog...

- Data on PFIC types 1, 2, 3 submitted to support use across a wide range of patients - - EMA grants accelerated assessment , validates Marketing Authorization Application for odevixibat with o rphan d e...

The following slide deck was published by Albireo Pharma, Inc. in conjunction with this event. For further details see: Albireo Pharma (ALBO) Investor Presentation - Slideshow